- Home
- SQNS vs CUE Comparison
SQNS vs CUE Comparison
Compare SQNS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SQNS
- CUE
- Stock Information
- Founded
- SQNS 2003
- CUE 2014
- Country
- SQNS France
- CUE United States
- Employees
- SQNS N/A
- CUE N/A
- Industry
- SQNS Semiconductors
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- SQNS Technology
- CUE Health Care
- Exchange
- SQNS Nasdaq
- CUE Nasdaq
- Market Cap
- SQNS 46.5M
- CUE 48.0M
- IPO Year
- SQNS 2011
- CUE 2018
- Fundamental
- Price
- SQNS $1.42
- CUE $0.68
- Analyst Decision
- SQNS Strong Buy
- CUE Strong Buy
- Analyst Count
- SQNS 1
- CUE 3
- Target Price
- SQNS $7.50
- CUE $3.00
- AVG Volume (30 Days)
- SQNS 1.0M
- CUE 313.6K
- Earning Date
- SQNS 08-22-2025
- CUE 08-13-2025
- Dividend Yield
- SQNS N/A
- CUE N/A
- EPS Growth
- SQNS N/A
- CUE N/A
- EPS
- SQNS 2.16
- CUE N/A
- Revenue
- SQNS $38,858,000.00
- CUE $7,991,000.00
- Revenue This Year
- SQNS N/A
- CUE N/A
- Revenue Next Year
- SQNS $93.87
- CUE $23.84
- P/E Ratio
- SQNS $0.66
- CUE N/A
- Revenue Growth
- SQNS 40.06
- CUE 13.83
- 52 Week Low
- SQNS $0.95
- CUE $0.45
- 52 Week High
- SQNS $4.28
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- SQNS 36.54
- CUE 47.91
- Support Level
- SQNS $1.40
- CUE $0.65
- Resistance Level
- SQNS $1.51
- CUE $0.71
- Average True Range (ATR)
- SQNS 0.20
- CUE 0.08
- MACD
- SQNS -0.04
- CUE 0.00
- Stochastic Oscillator
- SQNS 15.89
- CUE 38.62
About SQNS Sequans Communications S.A.
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.